Annual report [Section 13 and 15(d), not S-K Item 405]

Consolidated Statements of Stockholders' Equity

v3.26.1
Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Common Stock
Preferred Stock
Treasury Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Loss
Accumulated Deficit
Non-Controlling Interest
Beginning balance, common (in shares) at Mar. 31, 2023   99,458,369            
Beginning balance at Mar. 31, 2023 $ 607,255 $ 10 $ 100 $ (71) $ 822,217 $ (41,945) $ (175,115) $ 2,059
Beginning balance, preferred (in shares) at Mar. 31, 2023     100,000          
Beginning balance, treasury (in shares) at Mar. 31, 2023       758,125        
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net loss (420,448)           (420,228) (220)
Foreign currency translation (6,271)         (7,010)   739
Exercise of stock options (in shares)   1,050,553            
Exercise of stock options 2,871       2,871      
Issuance of restricted shares and vesting of restricted units, net of share settlements for tax withholdings (in shares)   1,610,010            
Issuance of restricted shares and vesting of restricted units, net of share settlements for tax withholdings (1,286)       (1,286)      
Acquisition of non-controlling interests in Fyber N.V. (3,751)       (1,173)     (2,578)
Stock-based compensation expense 35,562       35,562      
Ending balance, common (in shares) at Mar. 31, 2024   102,118,932            
Ending balance at Mar. 31, 2024 213,932 $ 10 $ 100 $ (71) 858,191 (48,955) (595,343) 0
Ending balance, preferred (in shares) at Mar. 31, 2024     100,000          
Ending balance, treasury (in shares) at Mar. 31, 2024       758,125        
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net loss (92,099)           (92,099)  
Foreign currency translation (2,349)         (2,349)    
Exercise of stock options (in shares)   93,799            
Exercise of stock options 373       373      
Issuance of restricted shares and vesting of restricted units, net of share settlements for tax withholdings (in shares)   3,764,911            
Issuance of restricted shares and vesting of restricted units, net of share settlements for tax withholdings (465)       (465)      
Stock-based compensation expense $ 34,566       34,566      
Ending balance, common (in shares) at Mar. 31, 2025 105,977,642 105,977,642            
Ending balance at Mar. 31, 2025 $ 153,958 $ 10 $ 100 $ (71) 892,665 (51,304) (687,442) 0
Ending balance, preferred (in shares) at Mar. 31, 2025 100,000   100,000          
Ending balance, treasury (in shares) at Mar. 31, 2025 758,125     758,125        
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net loss $ (37,732)           (37,732)  
Foreign currency translation $ (462)         (462)    
Exercise of stock options (in shares) 1,276,341 1,276,341            
Exercise of stock options $ 2,313       2,313      
Issuance of restricted shares and vesting of restricted units, net of share settlements for tax withholdings (in shares)   3,116,084            
Issuance of restricted shares and vesting of restricted units, net of share settlements for tax withholdings (937)       (937)      
Issuance of common stock in connection with at-the-market offering, net of issuance costs (in shares)   9,945,136            
Issuance of common stock in connection with at-the-market offering, net of issuance costs 56,809       56,809      
Stock-based compensation expense $ 18,212       18,212      
Ending balance, common (in shares) at Mar. 31, 2026 120,315,203 120,315,203            
Ending balance at Mar. 31, 2026 $ 192,161 $ 10 $ 100 $ (71) $ 969,062 $ (51,766) $ (725,174) $ 0
Ending balance, preferred (in shares) at Mar. 31, 2026 100,000   100,000          
Ending balance, treasury (in shares) at Mar. 31, 2026 758,125     758,125